102 related articles for article (PubMed ID: 37212253)
1. Optimization of polygenic risk scores in BRCA1/2 pathogenic variant heterozygotes in epithelial ovarian cancer.
Flaum N; Bowes J; Smith MJ; Crosbie EJ; Edmondson R; Lophatananon A; Evans DG
Genet Med; 2023 Sep; 25(9):100898. PubMed ID: 37212253
[TBL] [Abstract][Full Text] [Related]
2. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.
Barnes DR; Rookus MA; McGuffog L; Leslie G; Mooij TM; Dennis J; Mavaddat N; Adlard J; Ahmed M; Aittomäki K; Andrieu N; Andrulis IL; Arnold N; Arun BK; Azzollini J; Balmaña J; Barkardottir RB; Barrowdale D; Benitez J; Berthet P; Białkowska K; Blanco AM; Blok MJ; Bonanni B; Boonen SE; Borg Å; Bozsik A; Bradbury AR; Brennan P; Brewer C; Brunet J; Buys SS; Caldés T; Caligo MA; Campbell I; Christensen LL; Chung WK; Claes KBM; Colas C; ; ; Collonge-Rame MA; Cook J; Daly MB; Davidson R; de la Hoya M; de Putter R; Delnatte C; Devilee P; Diez O; Ding YC; Domchek SM; Dorfling CM; Dumont M; Eeles R; Ejlertsen B; Engel C; Evans DG; Faivre L; Foretova L; Fostira F; Friedlander M; Friedman E; Frost D; Ganz PA; Garber J; Gehrig A; Gerdes AM; Gesta P; Giraud S; Glendon G; Godwin AK; Goldgar DE; González-Neira A; Greene MH; Gschwantler-Kaulich D; Hahnen E; Hamann U; Hanson H; Hentschel J; Hogervorst FBL; Hooning MJ; Horvath J; Hu C; Hulick PJ; Imyanitov EN; ; ; ; Isaacs C; Izatt L; Izquierdo A; Jakubowska A; James PA; Janavicius R; John EM; Joseph V; Karlan BY; Kast K; Koudijs M; Kruse TA; Kwong A; Laitman Y; Lasset C; Lazaro C; Lester J; Lesueur F; Liljegren A; Loud JT; Lubiński J; Mai PL; Manoukian S; Mari V; Mebirouk N; Meijers-Heijboer HEJ; Meindl A; Mensenkamp AR; Miller A; Montagna M; Mouret-Fourme E; Mukherjee S; Mulligan AM; Nathanson KL; Neuhausen SL; Nevanlinna H; Niederacher D; Nielsen FC; Nikitina-Zake L; Noguès C; Olah E; Olopade OI; Ong KR; O'Shaughnessy-Kirwan A; Osorio A; Ott CE; Papi L; Park SK; Parsons MT; Pedersen IS; Peissel B; Peixoto A; Peterlongo P; Pfeiler G; Phillips KA; Prajzendanc K; Pujana MA; Radice P; Ramser J; Ramus SJ; Rantala J; Rennert G; Risch HA; Robson M; Rønlund K; Salani R; Schuster H; Senter L; Shah PD; Sharma P; Side LE; Singer CF; Slavin TP; Soucy P; Southey MC; Spurdle AB; Steinemann D; Steinsnyder Z; Stoppa-Lyonnet D; Sutter C; Tan YY; Teixeira MR; Teo SH; Thull DL; Tischkowitz M; Tognazzo S; Toland AE; Trainer AH; Tung N; van Engelen K; van Rensburg EJ; Vega A; Vierstraete J; Wagner G; Walker L; Wang-Gohrke S; Wappenschmidt B; Weitzel JN; Yadav S; Yang X; Yannoukakos D; Zimbalatti D; Offit K; Thomassen M; Couch FJ; Schmutzler RK; Simard J; Easton DF; Chenevix-Trench G; Antoniou AC;
Genet Med; 2020 Oct; 22(10):1653-1666. PubMed ID: 32665703
[TBL] [Abstract][Full Text] [Related]
3. Polygenic risk scores indicate extreme ages at onset of breast cancer in female BRCA1/2 pathogenic variant carriers.
Borde J; Laitman Y; Blümcke B; Niederacher D; Weber-Lassalle K; Sutter C; Rump A; Arnold N; Wang-Gohrke S; Horváth J; Gehrig A; Schmidt G; Dutrannoy V; Ramser J; Hentschel J; Meindl A; Schroeder C; Wappenschmidt B; Engel C; Kuchenbaecker K; Schmutzler RK; Friedman E; Hahnen E; Ernst C
BMC Cancer; 2022 Jun; 22(1):706. PubMed ID: 35761208
[TBL] [Abstract][Full Text] [Related]
4. Epithelial ovarian cancer risk: A review of the current genetic landscape.
Flaum N; Crosbie EJ; Edmondson RJ; Smith MJ; Evans DG
Clin Genet; 2020 Jan; 97(1):54-63. PubMed ID: 31099061
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of germline pathogenic
Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
[TBL] [Abstract][Full Text] [Related]
6. Polygenic risk modeling for prediction of epithelial ovarian cancer risk.
Dareng EO; Tyrer JP; Barnes DR; Jones MR; Yang X; Aben KKH; Adank MA; Agata S; Andrulis IL; Anton-Culver H; Antonenkova NN; Aravantinos G; Arun BK; Augustinsson A; Balmaña J; Bandera EV; Barkardottir RB; Barrowdale D; Beckmann MW; Beeghly-Fadiel A; Benitez J; Bermisheva M; Bernardini MQ; Bjorge L; Black A; Bogdanova NV; Bonanni B; Borg A; Brenton JD; Budzilowska A; Butzow R; Buys SS; Cai H; Caligo MA; Campbell I; Cannioto R; Cassingham H; Chang-Claude J; Chanock SJ; Chen K; Chiew YE; Chung WK; Claes KBM; Colonna S; ; ; ; Cook LS; Couch FJ; Daly MB; Dao F; Davies E; de la Hoya M; de Putter R; Dennis J; DePersia A; Devilee P; Diez O; Ding YC; Doherty JA; Domchek SM; Dörk T; du Bois A; Dürst M; Eccles DM; Eliassen HA; Engel C; Evans GD; Fasching PA; Flanagan JM; Fortner RT; Machackova E; Friedman E; Ganz PA; Garber J; Gensini F; Giles GG; Glendon G; Godwin AK; Goodman MT; Greene MH; Gronwald J; ; ; Hahnen E; Haiman CA; Håkansson N; Hamann U; Hansen TVO; Harris HR; Hartman M; Heitz F; Hildebrandt MAT; Høgdall E; Høgdall CK; Hopper JL; Huang RY; Huff C; Hulick PJ; Huntsman DG; Imyanitov EN; ; ; Isaacs C; Jakubowska A; James PA; Janavicius R; Jensen A; Johannsson OT; John EM; Jones ME; Kang D; Karlan BY; Karnezis A; Kelemen LE; Khusnutdinova E; Kiemeney LA; Kim BG; Kjaer SK; Komenaka I; Kupryjanczyk J; Kurian AW; Kwong A; Lambrechts D; Larson MC; Lazaro C; Le ND; Leslie G; Lester J; Lesueur F; Levine DA; Li L; Li J; Loud JT; Lu KH; Lubiński J; Mai PL; Manoukian S; Marks JR; Matsuno RK; Matsuo K; May T; McGuffog L; McLaughlin JR; McNeish IA; Mebirouk N; Menon U; Miller A; Milne RL; Minlikeeva A; Modugno F; Montagna M; Moysich KB; Munro E; Nathanson KL; Neuhausen SL; Nevanlinna H; Yie JNY; Nielsen HR; Nielsen FC; Nikitina-Zake L; Odunsi K; Offit K; Olah E; Olbrecht S; Olopade OI; Olson SH; Olsson H; Osorio A; Papi L; Park SK; Parsons MT; Pathak H; Pedersen IS; Peixoto A; Pejovic T; Perez-Segura P; Permuth JB; Peshkin B; Peterlongo P; Piskorz A; Prokofyeva D; Radice P; Rantala J; Riggan MJ; Risch HA; Rodriguez-Antona C; Ross E; Rossing MA; Runnebaum I; Sandler DP; Santamariña M; Soucy P; Schmutzler RK; Setiawan VW; Shan K; Sieh W; Simard J; Singer CF; Sokolenko AP; Song H; Southey MC; Steed H; Stoppa-Lyonnet D; Sutphen R; Swerdlow AJ; Tan YY; Teixeira MR; Teo SH; Terry KL; Terry MB; ; ; Thomassen M; Thompson PJ; Thomsen LCV; Thull DL; Tischkowitz M; Titus L; Toland AE; Torres D; Trabert B; Travis R; Tung N; Tworoger SS; Valen E; van Altena AM; van der Hout AH; Van Nieuwenhuysen E; van Rensburg EJ; Vega A; Edwards DV; Vierkant RA; Wang F; Wappenschmidt B; Webb PM; Weinberg CR; Weitzel JN; Wentzensen N; White E; Whittemore AS; Winham SJ; Wolk A; Woo YL; Wu AH; Yan L; Yannoukakos D; Zavaglia KM; Zheng W; Ziogas A; Zorn KK; Kleibl Z; Easton D; Lawrenson K; DeFazio A; Sellers TA; Ramus SJ; Pearce CL; Monteiro AN; Cunningham J; Goode EL; Schildkraut JM; Berchuck A; Chenevix-Trench G; Gayther SA; Antoniou AC; Pharoah PDP
Eur J Hum Genet; 2022 Mar; 30(3):349-362. PubMed ID: 35027648
[TBL] [Abstract][Full Text] [Related]
7. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
8. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
Le Page C; Rahimi K; Rodrigues M; Heinzelmann-Schwarz V; Recio N; Tommasi S; Bataillon G; Portelance L; Golmard L; Meunier L; Tonin PN; Gotlieb W; Yasmeen A; Ray-Coquard I; Labidi-Galy SI; Provencher D; Mes-Masson AM
Gynecol Oncol; 2020 Feb; 156(2):377-386. PubMed ID: 31753525
[TBL] [Abstract][Full Text] [Related]
10. High detection rate from genetic testing in BRCA-negative women with familial epithelial ovarian cancer.
Flaum N; Crosbie EJ; Edmondson R; Woodward ER; Lalloo F; Smith MJ; Schlecht H; Evans DG
Genet Med; 2022 Dec; 24(12):2578-2586. PubMed ID: 36169650
[TBL] [Abstract][Full Text] [Related]
11. Frequency of germline BRCA1/2 mutations and association with clinicopathological characteristics in Turkish women with epithelial ovarian cancer.
Sunar V; Korkmaz V; Topcu V; Cavdarli B; Arik Z; Ozdal B; Ustun YE
Asia Pac J Clin Oncol; 2022 Feb; 18(1):84-92. PubMed ID: 33629534
[TBL] [Abstract][Full Text] [Related]
12. Difference in Risk of Breast and Ovarian Cancer According to Putative Functional Domain Regions in Korean BRCA1/2 Mutation Carriers.
Park JS; Lee ST; Han JW; Kim TI; Nam EJ; Park HS
Clin Breast Cancer; 2018 Oct; 18(5):362-373.e1. PubMed ID: 29673794
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J; Lubinski J; Gronwald J; Cybulski C; Demsky R; Neuhausen SL; Kim-Sing C; Tung N; Friedman S; Senter L; Weitzel J; Karlan B; Moller P; Sun P; Narod SA;
Int J Cancer; 2015 Sep; 137(5):1136-46. PubMed ID: 25482078
[TBL] [Abstract][Full Text] [Related]
14. Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.
Zhang Y; Wu H; Yu Z; Li L; Zhang J; Liang X; Huang Q
BMC Cancer; 2022 Aug; 22(1):842. PubMed ID: 35918668
[TBL] [Abstract][Full Text] [Related]
15. A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history.
Gómez García EB; Oosterwijk JC; Timmermans M; van Asperen CJ; Hogervorst FB; Hoogerbrugge N; Oldenburg R; Verhoef S; Dommering CJ; Ausems MG; van Os TA; van der Hout AH; Ligtenberg M; van den Ouweland A; van der Luijt RB; Wijnen JT; Gille JJ; Lindsey PJ; Devilee P; Blok MJ; Vreeswijk MP
Breast Cancer Res; 2009; 11(1):R8. PubMed ID: 19200354
[TBL] [Abstract][Full Text] [Related]
16. Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and Ovarian Cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?
Infante M; Arranz-Ledo M; Lastra E; Abella LE; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232793
[TBL] [Abstract][Full Text] [Related]
17. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.
Arts-de Jong M; de Bock GH; van Asperen CJ; Mourits MJ; de Hullu JA; Kets CM
Eur J Cancer; 2016 Jul; 61():137-45. PubMed ID: 27209246
[TBL] [Abstract][Full Text] [Related]
18. Prevalence, spectrum, and founder effect of BRCA1 and BRCA2 mutations in epithelial ovarian cancer from the Middle East.
Siraj AK; Bu R; Iqbal K; Siraj N; Al-Haqawi W; Al-Badawi IA; Parvathareddy SK; Masoodi T; Tulbah A; Al-Dayel F; Al-Kuraya KS
Hum Mutat; 2019 Jun; 40(6):729-733. PubMed ID: 30825404
[TBL] [Abstract][Full Text] [Related]
19. Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.
Kotsopoulos J; Gronwald J; McCuaig JM; Karlan BY; Eisen A; Tung N; Bordeleau L; Senter L; Eng C; Couch F; Fruscio R; Weitzel JN; Olopade O; Singer CF; Pal T; Foulkes WD; Neuhausen SL; Sun P; Lubinski J; Narod SA;
Gynecol Oncol; 2020 Dec; 159(3):820-826. PubMed ID: 33010967
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
Cotrim DP; Ribeiro ARG; Paixão D; de Queiroz Soares DC; Jbili R; Pandolfi NC; Cezana C; de Cássia Mauro C; Mantoan H; Bovolim G; de Brot L; Torrezan GT; Carraro DM; Baiocchi G; da Cruz Formiga MN; da Costa AABA
BMC Cancer; 2019 Jan; 19(1):4. PubMed ID: 30606148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
